GlassScriptPhysician profile
William E Alldredge
NPI 1801904636
$15,046.73
in general payments reported to CMS, 2019-2025
69 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,078 · 2020: $1,405 · 2021: $1,922 · 2022: $1,916 · 2023: $1,689 · 2024: $1,539 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.69 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $4,151.74 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $1,442.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $849.31 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $793.53 | 2019-2025 | |
| Abbvie INC. | $772.12 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $539.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.37 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $498.44 | 2020-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $464.96 | 2021-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $415.21 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.95 | 2022-2025 | |
| Dexcom, INC. | $305.67 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Allergan, INC. | $261.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $259.73 | 2019-2025 | Trelegy Ellipta |
| Eisai INC. | $228.97 | 2020-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Alldredge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.